Progress in personalizing chemotherapy for bladder cancer

Advances in Urology

Volumn , Issue , 2012, Pages

  Chang, James S ^a   Lara, Primo N ^a   Pan, Chong Xian ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858226599     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/364919     Document Type: Review

References (96)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. McConkey D. J., Lee S., Choi W., Tran M., Majewski T., Lee S., Siefker-Radtke A., Dinney C., Czerniak B., Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression Urologic Oncology 2010 28 4 429 440
3. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Kiemeney L., Kriegmair M., Montironi R., Murphy W. M., Sesterhenn I. A., Tachibana M., Weider J., Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 2005 66 6 4 34 (Pubitemid 43049607)
4. Cookson M. S., Herr H. W., Zhang Z. F., Soloway S., Sogani P. C., Fair W. R., The treated natural history of high risk superficial bladder cancer: 15- year outcome Journal of Urology 1997 158 1 62 67 (Pubitemid 27251595)
5. Soloway M. S., Sofer M., Vaidya A., Contemporary management of stage T1 transitional cell carcinoma of the bladder Journal of Urology 2002 167 4 1573 1583 (Pubitemid 34240678)
6. Raghavan D., Shipley W. U., Garnick M. B., Russell P. J., Richie J. P., Biology and management of bladder cancer New England Journal of Medicine 1990 322 16 1129 1138 (Pubitemid 20149531)
7. Von Der Maase H., Sengelov L., Roberts J. T., Ricci S., Dogliotti L., Oliver T., Moore M. J., Zimmermann A., Arning M., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer Journal of Clinical Oncology 2005 23 21 4602 4608 (Pubitemid 46224062)
8. Bepler G., Begum M., Simon G. R., Molecular analysis-based treatment strategies for non-small cell lung cancer Cancer Control 2008 15 2 130 139
9. Gschwend J. E., Dahm P., Fair W. R., Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy European Urology 2002 41 4 440 448 (Pubitemid 35333942)
10. Quek M. L., Stein J. P., Nichols P. W., Cai J., Miranda G., Groshen S., Daneshmand S., Skinner E. C., Skinner D. G., Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy Journal of Urology 2005 174 1 103 106 (Pubitemid 40825683)
11. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists The Lancet 1999 354 9178 533 540
12. Grossman H. B., Natale R. B., Tangen C. M., Speights V. O., Vogelzang N. J., Trump D. L., DeVere White R. W., Sarosdy M. F., Wood D. P., Raghavan D., Crawford E. D., Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer New England Journal of Medicine 2003 349 9 859 866 (Pubitemid 37025405)
13. Griffiths G., Hall R., Sylvester R., International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial Journal of Clinical Oncology 2011 29 16 2171 2177
14. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration European Urology 2005 48 2 202 206
15. Hussain M. H. A., Wood D. P., Bajorin D. F., Bochner B. H., Dreicer R., Lamm D. L., O'Donnell M. A., Siefker-Radtke A. O., Theodorescu D., Dinney C. P., Bladder cancer: narrowing the gap between evidence and practice Journal of Clinical Oncology 2009 27 34 5680 5684
16. David K. A., Milowsky M. I., Ritchey J., Carroll P. R., Nanus D. M., Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base Journal of Urology 2007 178 2 451 454 (Pubitemid 47030482)
17. Fedeli U., Fedewa S. A., Ward E. M., Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007 Journal of Urology 2011 185 1 72 78
18. Skinner D. G., Daniels J. R., Russell C. A., Lieskovsky G., Boyd S. D., Nichols P., Kern W., Sakamoto J., Krailo M., Groshen S., The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial Journal of Urology 1991 145 3 459 467
19. Stockle M., Meyenburg W., Wellek S., Voges G., Gertenbach U., Thuroff J. W., Huber C., Hohenfellner R., Yagoda A., Droller M. J., Vogelzang N. J., Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study Journal of Urology 1992 148 2 302 307
20. Lehmann J., Franzaring L., Throff J., Wellek S., Stckle M., Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer BJU International 2006 97 1 42 47
21. Studer U. E., Bacchi M., Biedermann C., Jaeger P., Kraft R., Mazzucchelli L., Markwalder R., Senn E., Sonntag R. W., Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial Journal of Urology 1994 152 1 81 84 (Pubitemid 24175706)
22. Sylvester R., Sternberg C., The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why Annals of Oncology 2000 11 7 851 856
23. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration European Urology 2005 48 2 189 201
24. Svatek R. S., Shariat S. F., Lasky R. E., Skinner E. C., Novara G., Lerner S. P., Fradet Y., Bastian P. J., Kassouf W., Karakiewicz P. I., Fritsche H. M., Mller S. C., Izawa J. I., Ficarra V., Sagalowsky A. I., Schoenberg M. P., Siefker-Radtke A. O., Millikan R. E., Dinney C. P. N., The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder Clinical Cancer Research 2010 16 17 4461 4467
25. Loehrer P. J. Sr., Einhorn L. H., Elson P. J., Crawford E. D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M. F., Lowe B. A., Blumenstein B., Trump D., A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study Journal of Clinical Oncology 1992 10 7 1066 1073
26. Von der Maase H., Hansen S. W., Roberts J. T., Dogliotti L., Oliver T., Moore M. J., Bodrogi I., Albers P., Knuth A., Lippert C. M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S. P., Roychowdhury D. F., Tomlin I., Visseren-Grul C. M., Conte P. F., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study Journal of Clinical Oncology 2000 18 17 3068 3077
27. Sternberg C. N., De Mulder P. H. M., Schornagel J. H., Théodore C., Fossa S. D., Van Oosterom A. T., Witjes F., Spina M., Van Groeningen C. J., De Balincourt C., Collette L., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european organization for research and treatment of cancer protocol no. 30924 Journal of Clinical Oncology 2001 19 10 2638 2646 (Pubitemid 32441368)
28. Sternberg C. N., De Mulder P., Schornagel J. H., Theodore C., Fossa S. D., Van Oosterom A. T., Witjes J. A., Spina M., Van Groeningen C. J., Duclos B., Roberts J. T., De Balincourt C., Collette L., Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours European Journal of Cancer 2006 42 1 50 54 (Pubitemid 41814532)
29. Bochner B. H., Dalbagni G., Kattan M. W., Fearn P., Vora K., Hee S. S., Zoref L., Abol-Enein H., Ghoneim M. A., Scardino P. T., Bajorin D., Skinner D. G., Stein J. P., Miranda G., Gschwend J. E., Volkmer B. G., Hautmann R. E., Chang S., Cookson M., Smith J. A., Thalman G., Studer U. E., Lee C. T., Montie J., Wood D., Palou J., Fradet Y., LaCombe L., Simard P., Schoenberg M. P., Lerner S., Vazina A., Bassi P., Murai M., Kikuchi E., Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer Journal of Clinical Oncology 2006 24 24 3967 3972 (Pubitemid 46630745)
30. Karakiewicz P. I., Shariat S. F., Palapattu G. S., Gilad A. E., Lotan Y., Rogers C. G., Vazina A., Gupta A., Bastian P. J., Perrotte P., Sagalowsky A. I., Schoenberg M., Lerner S. P., Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder Journal of Urology 2006 176 4 1354 1362 (Pubitemid 44307209)
31. Vazquez A., Bond E. E., Levine A. J., Bond G. L., The genetics of the p53 pathway, apoptosis and cancer therapy Nature Reviews Drug Discovery 2008 7 12 979 987
32. Esrig D., Elmajian D., Groshen S., Freeman J. A., Stein J. P., Chen-S. C., Nichols P. W., Skinner D. G., Jones P. A., Cote R. J., Accumulation of nuclear p53 and tumor progression in bladder cancer New England Journal of Medicine 1994 331 19 1259 1264 (Pubitemid 24333190)
33. Sarkis A. S., Dalbagni G., Cordon-Cardo C., Zhang Z. F., Sheinfeld J., Fair W. R., Herr H. W., Reuter V. E., Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression Journal of the National Cancer Institute 1993 85 1 53 59 (Pubitemid 23023225)
34. Malats N., Bustos A., Nascimento C. M., Fernandez F., Rivas M., Puente D., Kogevinas M., Real F. X., P53 as a prognostic marker for bladder cancer: a meta-analysis and review The Lancet Oncology 2005 6 9 678 686 (Pubitemid 41222758)
35. Ferreira C. G., Tolis C., Giaccone G., p53 and chemosensitivity Annals of Oncology 1999 10 9 1011 1021 (Pubitemid 29482455)
36. Cote R. J., Esrig D., Groshen S., Jones P. A., Skinner D. G., Lowe S. W., Jacks T., p53 and treatment of bladder cancer Nature 1997 385 6612 123 125
37. Stadler W. M., Lerner S. P., Groshen S., Stein J. P., Shi S. -R., Raghavan D., Esrig D., Steinberg G., Wood D., Klotz L., Hall C., Skinner D. G., Cote R. J., Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status Journal of Clinical Oncology 2011 29 25 3443 3449
38. Park C. H., Bessho T., Matsunaga T., Sancar A., Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease Journal of Biological Chemistry 1995 270 39 22657 22660
39. Gossage L., Madhusudan S., Current status of excision repair cross complementing-group 1 (ERCC1) in cancer Cancer Treatment Reviews 2007 33 6 565 577 (Pubitemid 47355341)
40. Vilmar A. C., Santoni-Rugiu E., Srensen J. B., ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial Annals of Oncology 2010 21 9 1817 1824
41. Bellmunt J., Paz-Ares L., Cuello M., Cecere F. L., Albiol S., Guillem V., Gallardo E., Carles J., Mendez P., de la Cruz J. J., Taron M., Rosell R., Baselga J., Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Annals of Oncology 2007 18 3 522 528 (Pubitemid 46359633)
42. Hoffmann A. C., Wild P., Leicht C., Bertz S., Danenberg K. D., Danenberg P. V., Sthr R., Stckle M., Lehmann J., Schuler M., Hartmann A., MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotheraphy Neoplasia 2010 12 8 628 636
43. Kim K. H., Do I. G., Kim H. S., Chang M. H., Kim H. S., Jun H. J., Uhm J., Yi S. Y., Lim D. H., Ji S. H., Park M. J., Lee J., Park S. H., Kwon G. Y., Lim H. Y., Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy APMIS 2010 118 12 941 948
44. Elledge S. J., Zhou Z., Allen J. B., Ribonucleotide reductase: regulation, regulation, regulation Trends in Biochemical Sciences 1992 17 3 119 123
45. Gautam A., Li Z. R., Bepler G., RRM1-induced metastasis suppression through PTEN-regulated pathways Oncogene 2003 22 14 2135 2142 (Pubitemid 36539563)
46. Bepler G., Sharma S., Cantor A., Gautam A., Haura E., Simon G., Sharma A., Sommers E., Robinson L., RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer Journal of Clinical Oncology 2004 22 10 1878 1885 (Pubitemid 41095179)
47. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G., DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer New England Journal of Medicine 2007 356 8 800 808 (Pubitemid 46294612)
48. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., Simon G., RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer Journal of Clinical Oncology 2006 24 29 4731 4737 (Pubitemid 46646245)
49. Harshman L. C., Bepler G., Zheng Z., Higgins J. P., Allen G. I., Srinivas S., Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients BJU International 2010 106 11 1805 1811
50. Mackey J. R., Mani R. S., Selner M., Mowles D., Young J. D., Belt J. A., Crawford C. R., Cass C. E., Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Research 1998 58 19 4349 4357 (Pubitemid 28450036)
51. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J. D., Dumontet C., Cass C., Lai R., Mackey J. R., The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clinical Cancer Research 2004 10 20 6956 6961 (Pubitemid 39383046)
52. Maréchal R., Mackey J. R., Lai R., Demetter P., Peeters M., Polus M., Cass C. E., Young J., Salmon I., Devire J., Van Laethem J. L., Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapyin resected pancreatic adenocarcinoma Clinical Cancer Research 2009 15 8 2913 2919
53. Sve P., Mackey J. R., Isaac S., Trédan O., Souquet P. J., Pérol M., Cass C., Dumontet C., CN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer Lung Cancer 2005 49 3 363 370 (Pubitemid 41139149)
54. Mey V., Giovannetti E., De Braud F., Nannizzi S., Curigliano G., Verweij F., De Cobelli O., Pece S., Del Tacca M., Danesi R., In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients British Journal of Cancer 2006 95 3 289 297 (Pubitemid 44187589)
55. Matsumura N., Nakamura Y., Kohjimoto Y., Inagaki T., Nanpo Y., Yasuoka H., Ohashi Y., Hara I., The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy BJU International 2011 108 2 E110 E116
56. Wang Q., Zhang H., Fishel R., Greene M. I., BRCA1 and cell signaling Oncogene 2000 19 53 6152 6158 (Pubitemid 32059466)
57. Quinn J. E., James C. R., Stewart G. E., Mulligan J. M., White P., Chang G. K. F., Mullan P. B., Johnston P. G., Wilson R. H., Harkin D. P., BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clinical Cancer Research 2007 13 24 7413 7420
58. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M. S., Queralt C., Majo J., Sanchez J. M., Sanchez J. J., Maestre J., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Human Molecular Genetics 2004 13 20 2443 2449 (Pubitemid 39377848)
59. Font A., Taron M., Gago J. L., Costa C., Snchez J. J., Carrato C., Mora M., Celiz P., Perez L., Rodrguez D., Gimenez-Capitan A., Quiroga V., Benlloch S., Ibarz L., Rosell R., BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer Annals of Oncology 2011 22 1 139 144
60. Tada Y., Wada M., Kuroiwa K., Kinugawa N., Harada T., Nagayama J., Nakagawa M., Naito S., Kuwano M., MRD1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment Clinical Cancer Research 2000 6 12 4618 4627 (Pubitemid 32110396)
61. Adams J. M., Cory S., The Bcl-2 protein family: arbiters of cell survival Science 1998 281 5381 1322 1326 (Pubitemid 28406819)
62. Kong G., Shin K. Y., Oh Y. H., Lee J. J., Park H. Y., Woo Y. N., Lee J. D., Bcl-2 and p53 expressions in invasive bladder cancers Acta Oncologica 1998 37 7-8 715 720 (Pubitemid 29066826)
63. Ong F., Moonen L. M. F., Gallee M. P. W., Ten Bosch C., Zerp S. F., Hart A. A. M., Bartelink H., Verheij M., Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53 Radiotherapy and Oncology 2001 61 2 169 175 (Pubitemid 33016577)
64. Karam J. A., Lotan Y., Karakiewicz P. I., Ashfaq R., Sagalowsky A. I., Roehrborn C. G., Shariat S. F., Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy The Lancet Oncology 2007 8 2 128 136 (Pubitemid 46158371)
65. Lee R. C., Feinbaum R. L., Ambros V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 1993 75 5 843 854 (Pubitemid 24014542)
66. Wightman B., Ha I., Ruvkun G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans Cell 1993 75 5 855 862 (Pubitemid 24014543)
67. Lee Y. S., Dutta A., MicroRNAs in cancer Annual Review of Pathology 2009 4 199 227
68. Catto J. W. F., Alcaraz A., Bjartell A. S., De Vere White R., Evans C. P., Fussel S., Hamdy F. C., Kallioniemi O., Mengual L., Schlomm T., Visakorpi T., MicroRNA in prostate, bladder, and kidney cancer: a systematic review European Urology 2011 59 671 681
69. Han Y., Chen J., Zhao X., Liang C., Wang Y., Sun L., Jiang Z., Zhang Z., Yang R., Chen J., Li Z., Tang A., Li X., Ye J., Guan Z., Gui Y., Cai Z., MicroRNA expression signatures of bladder cancer revealed by deep sequencing PLoS One 2011 6 3
70. Li X., Chen J., Hu X., Huang Y., Li Z., Zhou L., Tian Z., Ma H., Wu Z., Chen M., Han Z., Peng Z., Zhao X., Liang C., Wang Y., Sun L., Chen J., Zhao J., Jiang B., Yang H., Gui Y., Cai Z., Zhang X., Comparative mRNA and microrna expression profiling of three genitourinary cancers reveals common hallmarks and Cancer-Specific molecular events PLoS One 2011 6 7
71. Bommer G. T., Gerin I., Feng Y., Kaczorowski A. J., Kuick R., Love R. E., Zhai Y., Giordano T. J., Qin Z. S., Moore B. B., MacDougald O. A., Cho K. R., Fearon E. R., p53-mediated activation of miRNA34 candidate tumor-suppressor genes Current Biology 2007 17 15 1298 1307 (Pubitemid 47176893)
72. Welch C., Chen Y., Stallings R. L., MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells Oncogene 2007 26 34 5017 5022 (Pubitemid 47172643)
73. Vinall R. L., Zripoll A., Wang S., MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. International Journal of Cancer. In press
74. Takata R., Katagiri T., Kanehira M., Tsunoda T., Shuin T., Miki T., Namiki M., Kohri K., Matsushita Y., Fujioka T., Nakamura Y., Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling Clinical Cancer Research 2005 11 7 2625 2636 (Pubitemid 40569463)
75. Takata R., Katagiri T., Kanehira M., Shuin T., Miki T., Namiki M., Kohri K., Tsunoda T., Fujioka T., Nakamura Y., Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy Cancer Science 2007 98 1 113 117 (Pubitemid 44803929)
76. Lee J. K., Havaleshko D. M., Cho H., Weinstein J. N., Kaldjian E. P., Karpovich J., Grimshaw A., Theodorescu D., A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery Proceedings of the National Academy of Sciences of the United States of America 2007 104 32 13086 13091 (Pubitemid 351737597)
77. Williams P. D., Cheon S., Havaleshko D. M., Jeong H., Cheng F., Theodorescu D., Lee J. K., Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy Cancer Research 2009 69 21 8302 8309
78. Matsuoka S., Ballif B. A., Smogorzewska A., McDonald E. R., Hurov K. E., Luo J., Bakalarski C. E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S. P., Elledge S. J., ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage Science 2007 316 5828 1160 1166 (Pubitemid 46877472)
79. Henderson P. T., Pan C. X., Human microdosing for the prediction of patient response Bioanalysis 2010 2 3 373 376
80. Henderson P. T., Li T., He M., Zhang H., Malfatti M., Gandara D., Grimminger P. P., Danenberg K. D., Beckett L., De Vere White R. W., Turteltaub K. W., Pan C. -X., A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance International Journal of Cancer 2011 129 6 1425 1434
81. Parker R. J., Gill I., Tarone R., Vionnet J. A., Grunberg S., Muggia F. M., Reed E., Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry Carcinogenesis 1991 12 7 1253 1258
82. Bonetti A., Apostoli P., Zaninelli M., Pavanel F., Colombatti M., Cetto G. L., Franceschi T., Sperotto L., Leone R., Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy Clinical Cancer Research 1996 2 11 1829 1835 (Pubitemid 26384149)
83. Fichtinger-Schepman A. M. J., Van Der Velde-Visser S. D., Van Dijk-Knijnenburg H. C. M., Van Oosterom A. T., Baan R. A., Berends F., Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation Cancer Research 1990 50 24 7887 7894
84. Fisch M. J., Howard K. L., Einhorn L. H., Sledge G. W., Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival Clinical Cancer Research 1996 2 6 1063 1066 (Pubitemid 26198476)
85. Hoebers F. J. P., Pluim D., Hart A. A. M., Verheij M., Balm A. J. M., Fons G., Rasch C. R. N., Schellens J. H. M., Stalpers L. J. A., Bartelink H., Begg A. C., Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor Cancer Chemotherapy and Pharmacology 2008 61 6 1075 1081 (Pubitemid 351423118)
86. Motzer R. J., Reed E., Perera F., Tang D., Shamkhani H., Poirier M. C., Tsai-W. Y., Parker R. J., Bosl G. J., Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay Cancer 1994 73 11 2843 2852 (Pubitemid 24166275)
87. Reed E., Ozols R. F., Tarone R., Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy Proceedings of the National Academy of Sciences of the United States of America 1987 84 14 5024 5028 (Pubitemid 17095857)
88. Reed E., Parker R. J., Gill I., Bicher A., Dabholkar M., Vionnet J. A., Bostick- Bruton F., Tarone R., Muggia F. M., Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies Cancer Research 1993 53 16 3694 3699 (Pubitemid 23252027)
89. Schellens J. H. M., Ma J., Planting A. S. T., Van Der Burg M. E. L., Van Meerten E., De Boer-Dennert M., Schmitz P. I. M., Stoter G., Verweij J., Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours British Journal of Cancer 1996 73 12 1569 1575 (Pubitemid 26235386)
90. Van De Vaart P. J. M., Belderbos J., De Jong D., Sneeuw K. C. A., Majoor D., Bartelink H., Begg A. C., DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy International Journal of Cancer 2000 86 3 160 166 (Pubitemid 30185925)
91. Vogel J. S., Accelerator mass spectrometry for quantitative in vivo tracing BioTechniques 2005 25 29
92. Vogel J. S., Turteltaub K. W., Finkel R., Nelson D. E., Accelerator mass spectrometry: isotope quantification at attomole sensitivity Analytical Chemistry 1995 67 11 353A 359A
93. Guilderson T. P., Caldeira K., Duffy P. B., Radiocarbon as a diagnostic tracer in ocean and carbon cycle modeling Global Biogeochemical Cycles 2000 14 3 887 902
94. Wang D., Lippard S. J., Cellular processing of platinum anticancer drugs Nature Reviews Drug Discovery 2005 4 4 307 320 (Pubitemid 41130944)
95. Wang S., Zhang H., Malfatti M., De Vere White R., Lara P. N., Turteltaub K., Henderson P., Pan C. X., Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells Chemical Research in Toxicology 2010 23 11 1653 1655
96. Yang X., Flaig T. W., Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application International Brazilian Journal of Urology 2010 36 3 273 282